Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Acromegaly Article
This is a selection made from among articles on Drug Treatment Acromegaly. For a permanent link to this article, or to bookmark it for future reading, click here.
Issues Regarding Drug Testing
from: The argument that drug testing actually causes more harm to society rather than helping it as professed has been gaining ground in the last few years. Although drug testing was conceptualized and implemented with the purpose of reducing the damage that is being done to society by drugs, the reality of the effects of drug testing seems to be quite different. Drug testing has advanced into schools, the military and the workplace in a steady pace. The whole purpose is to promote a healthy environment free of drugs and promote the zero tolerance policy on drug abuse. But is the entire drug testing campaign actually reducing the drug abuse rate or is it really compounding the problem by driving the guilty party to the wall.
When a person is screened and found to be guilty of drug abuse, he is not always subjected to rehabilitation and assisted recovery as we may tend to believe. A person found to be abusing drugs may have to undergo imprisonment, may lose his job and even lose the custody of his children. The point of concern is that a person detected during drug testing could possibly undergo punishment that would actually reduce his ties with society and decrease the chances of his return to a normal life.
It is not just the workplace that is under the shadow of drug testing. Earlier drug testing in schools fell in the grey area of the law and was avoided for a while. But the US Supreme courts have now approved drug testing in students of public schools who participate in extracurricular activities like sports, and there is general consensus that this will expand to include all students in the future. A student who is tested and found to have used drugs can be expelled for this reason alone. Instead of rehabilitating the drug abuser into regular social life, what a drug test actually succeeds in doing is really denying the student a proper education pushing him farther into dependence on drugs.
Another perspective to this whole issue is the opinion that it is not really the treatment after a positive drug test that deters the person from further drug abuse; it is rather the threat of incarceration and punishment. Once drug testing has identified a drug abuser, the treatment given to release him from addiction is opined to be superfluous by a lobby that argues that it is the possibility of punishment and loss of employment that actually motivates the people to actually stop abusing drugs. This perspective emphasizes that after drug testing, punishment or the threat of it is necessary and in a way constructive in cleaning up the society of drug abusers.
It is to be noted the usual urine drug testing does not differentiate between a regular drug abuser and a one-time experimenter. When the drug testing results come back as positive, it does not contain information on when the person used the drug, nor does it contain info on how often he uses it.
What results from this is that both of these types of drug users are clumped together and people who just experimented with a recreational drug just once in their life time are labeled as drug abusers too.
About Author
This Article is written by Lena Butler, the author of TestCountry Drug FAQ, a longer version of this article is located at Issues Regarding Drug Testing, and resources from other home health and wellness testing articles are used such as TestCountry Drug Testing Kits.
Source: ArticleTrader.com
Drug Treatment Acromegaly Specific links
Drug Treatment Acromegaly News
Novartis Says Acromegaly Drug Met Primary Goal In Late-Stage Study - RTT News
Novartis Says Acromegaly Drug Met Primary Goal In Late-Stage Study RTT News (RTTNews) - Novartis International AG (NVS: News ) Monday said results from a late-stage study showed its novel therapy pasireotide LAR (long-acting release) to be more effective than the current standard medical therapy in patients with acromegaly - a ... Novartis drug pasireotide LAR shows superior efficacy compared to SandostatinR ... Novartis: Pasireotide Works Well In Acromegaly Trial Phase III study results show Novartis drug pasireotide LAR superior to ... |
New Drug Controls Growth Hormone Disease - MedPage Today
New Drug Controls Growth Hormone Disease MedPage Today Note that in this study significantly more patients with acromegaly treated with pasireotide experienced full control of their disease in terms of growth hormone levels and normalized IGF-1 levels than those taking octreotide. |
Novartis passes Phase III test for rare-disorder drug - FierceBiotech
Novartis passes Phase III test for rare-disorder drug FierceBiotech The Swiss drug giant says its experimental drug pasireotide LAR beat the standard of care in the largest Phase III study involving patients with acromegaly, which triggers overproduction of growth hormone and leads to enlarged feet, hands and organs. Novartis Scores in Phase III Study Novartis says Sandostatin successor clears phase III |
Novartis acromegaly treatment shows benefits in phase III trial - Zenopa
Novartis acromegaly treatment shows benefits in phase III trial Zenopa Novartis has published clinical data from a study that demonstrates the efficacy benefits of its new acromegaly treatment pasireotide LAR (long-acting release). The company has concluded the largest ever phase III study of acromegaly patients, ... |
Aegis Therapeutics Awarded Patent for Octreotide Formulations Suitable for ... - MarketWatch (press release)
Aegis Therapeutics Awarded Patent for Octreotide Formulations Suitable for ... MarketWatch (press release) ... found in many protein injectable drugs. Octreotide is a peptide hormone that mimics natural somatostatin pharmacologically. Octreotide is used to treat acromegaly, severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, ... |
Swiss stocks - Factors to watch on May 7 - Reuters
Swiss stocks - Factors to watch on May 7 Reuters NOVARTIS Swiss drugmaker Novartis said study data showed a new therapy for people suffering from acromegaly, a rare disorder characterised by enlargement of the feet, hands and internal organs, was more effective than the treatment now commonly ... |
Growing pains - New Straits Times
 New Straits Times | Growing pains New Straits Times Any hospital with a neurosurgery department should be able to carry out surgical therapy for acromegaly but it is crucial to consult an expert in pituitary surgery. “Medical therapy needs good drugs but surgical therapy needs a good pair of hands,” Dr ... |
Most cases of ulcerative colitis are treatable - Sarasota Herald-Tribune
 Sarasota Herald-Tribune | Most cases of ulcerative colitis are treatable Sarasota Herald-Tribune When the disease acts up, drugs from the cortisone family usually can bring the illness under control. Prednisone is the one most often prescribed. Newer medicines, called biologicals, can control the immune attack on the colon and are the latest ... |
Aegis Therapeutics Awarded Patent for Octreotide Formulations Suitable for ... - Marketwire (press release)
Aegis Therapeutics Awarded Patent for Octreotide Formulations Suitable for ... Marketwire (press release) ... found in many protein injectable drugs. Octreotide is a peptide hormone that mimics natural somatostatin pharmacologically. Octreotide is used to treat acromegaly, severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, ... |
Ipsen posts solid set of results, eyes US expansion - Pharma Times
Ipsen posts solid set of results, eyes US expansion Pharma Times Revenue growth was driven by Decapeptyl (triptorelin pamoate) for prostate cancer, which rose 4.3% to 68.0 million euros, while the French drugmaker's Somatuline (lanreotide) range of drugs for acromegaly and neuroendocrine tumours was up 18.7% to 54.7 ... |